How do you reconcile the differing results of the C-POST and KEYNOTE-630 trials when discussing treatment options with high-risk CSCC patients?  

I explain that the two trials enrolled different risk populations, which likely accounts for the apparent discrepancy in outcomes — but when you look closely, they actually lead to the same clinical conclusion. C-POST deliberately enriched for very-high-risk patients (using...

Identifying patients at the highest risk for cSCC disease relapse is crucial and likely accounts for the difference in outcomes between the C-POST (adjuvant cemiplimab is highly effective to prevent relapse) and KEYNOTE-630 (adjuvant pembrolizumab is not effective) trials. The outcomes from the KEYN...

It is hard to compare across these two randomized, placebo-controlled phase 3 trials, particularly when there are differences in how they define high-risk cSCC, and the different patient characteristics in these two trials. The C-POST trial showed a very compelling efficacy for its primary endpoint ...